Immunocore Holdings Earnings Call Transcripts
Fiscal Year 2026
-
The platform enables broad targeting of cancer and immune diseases, with KIMMTRAK driving strong revenue and global growth. Key upcoming milestones include pivotal data readouts in melanoma, HIV, and autoimmune programs, supported by a robust cash position and strategic flexibility.
-
KIMMTRAK continues to drive strong commercial growth and is expanding into new indications, with pivotal data readouts expected in cutaneous melanoma, lung, and ovarian cancer in 2024. The pipeline also advances in HIV and autoimmune diseases, supported by a robust cash position and strategic investments.
-
The conference highlighted strong commercial growth for KIMMTRAK, with significant expansion plans in melanoma and new tumor types. Multiple phase III trials and pipeline assets, including PRAME and PIWIL1, are advancing, with major data readouts expected from 2026 onward.
Fiscal Year 2025
-
KIMMTRAK delivered $400M in 2025 net sales (29% YoY growth), with strong global adoption and a robust pipeline spanning oncology, infectious disease, and autoimmune. Three phase III trials are ongoing, and key data readouts are expected in 2026, supported by $864M in cash.
-
The conference highlighted strong commercial growth for KIMMTRAK, robust pipeline progress in oncology, infectious disease, and autoimmune programs, and a solid financial position with $892 million in cash. Key upcoming milestones include multiple Phase 3 trial readouts and new clinical data across indications.
-
AI and global partnerships drive innovation and efficiency, while KIMMTRAK's market penetration nears maturity with ongoing expansion. Multiple phase 3 trials and a robust pipeline in oncology, autoimmune, and infectious diseases are supported by strong financials and disciplined spending.
-
The company is advancing multiple late-stage trials, with KIMMTRAK showing strong commercial performance and extended patent protection. Key data readouts in 2026, especially for TEBE-AM and PRAME, are expected to drive significant value, while pipeline programs in oncology and infectious diseases progress toward pivotal milestones.
-
KIMMTRAK delivered strong H1 2025 results with $192M in revenue, 32% growth year-over-year, and robust U.S. and European performance. Three Phase III trials are progressing, with continued pipeline expansion and a strong cash position supporting future growth.
-
KIMMTRAK continues robust growth with strong US and international penetration, extended therapy duration, and a leading survival benefit. Multiple pivotal trials in melanoma and new pipeline programs, including PRAME and PWIL, are advancing, with key data readouts expected over the next two years.
-
The session highlighted robust commercial growth, innovative TCR-based therapies, and a diverse pipeline spanning oncology, infectious disease, and autoimmune indications. Key clinical milestones are expected in the next 12–18 months, with strategic focus on data-driven development and potential partnerships.
-
No supply chain or regulatory disruptions have been observed, and gross margins remain strong. HIV and HBV clinical programs are progressing, with new data expected in 12–18 months. KIMMTRAK continues to drive growth, with expansion into new markets and a robust pipeline of oncology trials underway.
-
A robust late-stage pipeline is advancing in oncology, infectious, and autoimmune diseases, with KIMMTRAK driving strong revenue growth and new indications potentially expanding the patient base. Key data readouts for KIMMTRAK, PRAME, HIV, and PIWIL1 are expected within 12–18 months.
-
A diversified late-stage pipeline is advancing with KIMMTRAK’s global expansion and strong growth, supported by ongoing phase III trials in melanoma and new programs in oncology, infectious disease, and autoimmune diseases. Key data readouts and regulatory milestones are expected over the next 12–18 months.
Fiscal Year 2024
-
Reported $310M in 2024 revenue, up 30% year-on-year, driven by KIMMTRAK's global expansion and strong U.S. growth. Advanced three phase III melanoma trials and expanded pipeline in infectious and autoimmune diseases, with robust cash reserves supporting future R&D.
-
PRAME and KIMMTRAK oncology programs advance with global Phase III trials and strong commercial growth, while the platform expands into autoimmune and HIV, targeting transformative therapies. Key data readouts are expected in 2025 and 2026.
-
Strong commercial growth continues with Kimmtrak, driven by high market penetration and expanding launches. Pipeline advances include promising data and timelines for cutaneous melanoma, PRAME, and PIWIL1, while the HIV program targets a functional cure with key data expected next year.
-
Pioneering T-cell receptor bispecifics, the company reported strong KIMMTRAK sales growth, robust financials, and expanding global reach. Multiple phase III trials and new indications, including HIV and solid tumors, are advancing, with key data readouts expected in 2025.
-
KIMMTRAK net sales grew 34% year-over-year to $146M in H1 2024, driven by strong U.S. performance and global expansion. Pipeline progress includes accelerated phase III trials in melanoma and promising early data in ovarian, lung, and HIV, with robust cash reserves supporting future growth.
-
Recent data show PRAME achieves high disease control in melanoma, with phase III trials underway and data expected in 2027. Ovarian and lung cancer cohorts are advancing, and KIMMTRAK's cutaneous melanoma program is accelerated, with final results anticipated in 2026.